Geron (GERN) Stifel 2026 Targeted Oncology Virtual Forum summary

Commercial progress and strategy

• Transitioned from a development-stage to a commercial company, focusing on awareness and engagement with the hematology community.

• Reported $184 million in net revenue for 2025, with 2026 guidance of $220–$240 million.

• Key internal metrics include new account additions, breadth of reach, and patient line of therapy distribution.

• Added 150 new accounts last quarter, with a growing share of patients in first- and second-line settings.

• Refined strategy to focus on the second-line patient setting, targeting approximately 8,000 U.S. patients.

Market dynamics and uptake

• NCCN guidelines updated in fall 2025, positioning RYTELO as a preferred second-line agent ahead of HMAs.

• Community physicians treat 80% of patients, but initial uptake was balanced between academic and community centers.

• Community adoption is accelerating as academic centers gain experience and share best practices.

• Messaging around cytopenia as a biomarker for response has improved patient management and persistency.

• Real-world data from Moffitt Cancer Center shows outcomes consistent with or better than clinical trials.

Clinical data and future opportunities

• Cytopenia correlates with robust and durable responses, with most patients recovering within weeks and no major safety concerns.

• Long-term safety data at 45 months show improved OS, PFS, and leukemia conversion rates.

• Real-world and investigator-initiated studies indicate strong interest and potential for broader use, including off-label in frontline settings.

• Imetelstat works across the EPO serum spectrum, potentially offering advantages over ESAs.

• Upcoming interim OS analysis for myelofibrosis (IMpactMF) expected before year-end, with DMC oversight and limited patient crossover.